INFevo raises over RMB100m in Pre-A for virtual-cell AI
INFevo, an AI-for-science spin-out from XtalPi, has raised more than RMB100m in a Pre-A round to build virtual-cell models of how cells respond to drugs.
What happened
INFevo, an AI-for-science company spun out of XtalPi, raised more than RMB100m in a Pre-A round on 16 November. Xinglian Capital, Prosperity7, Huagai Capital, Huakong Fund and Detong Capital invested, with Shunwei Capital, Sequoia China and Songhe Capital following on. The company called it the largest single round for a Chinese virtual-cell company.
The numbers
- Round size: more than RMB100m.
- Stage: Pre-A.
- New investors: Xinglian Capital, Prosperity7, Huagai Capital, Huakong Fund, Detong Capital.
- Existing investors: Shunwei Capital, Sequoia China, Songhe Capital.
- Prior round: angel, June 2026.
Why it matters
INFevo combines virtual-cell models with automated experiments to predict how cells respond to candidate drugs. The aim is to shorten the cycle from target discovery to clinical testing, moving AI from molecule design to modelling biology. If it works, the proprietary data set becomes the moat.
The counter-argument is that virtual-cell prediction is unproven at clinical scale, and the company's claim to the largest round in its niche is self-reported. The blue-chip cap table and the XtalPi lineage are strong signals, but the test is whether a model-derived candidate reaches the clinic.
What to watch
- A first clinical candidate or pharma partnership.
- How the platform is priced for global pharma users.
- Whether XtalPi's parentage helps or complicates overseas expansion.
Original source: Sina Finance · 16 Nov 2026
